Determining the Cut-Off Value of the MASCC Score to Predict Mortality in Hospitalized Febrile Neutropenic Patients: A Decade-Long Single-Center Retrospective Cohort Study.

IF 2.5 3区 医学 Q3 ONCOLOGY
Oncology Pub Date : 2025-04-24 DOI:10.1159/000546029
Yasemin Nadir, Pinar Kiran, Damla Erturk, Hale Bulbul, Mustafa Degirmenci, Suheyla Serin Senger
{"title":"Determining the Cut-Off Value of the MASCC Score to Predict Mortality in Hospitalized Febrile Neutropenic Patients: A Decade-Long Single-Center Retrospective Cohort Study.","authors":"Yasemin Nadir, Pinar Kiran, Damla Erturk, Hale Bulbul, Mustafa Degirmenci, Suheyla Serin Senger","doi":"10.1159/000546029","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Febrile neutropenia (FN) is linked to significant morbidity and mortality in cancer patients. Therefore, our study aimed to determine the cut-off value of the MASCC score to predict mortality in hospitalized FN patients.</p><p><strong>Methods: </strong>We included 354 hospitalized cancer patients, divided into two groups: the mortality group (n = 116) and the survival group (n = 238). We defined risk factors of all-cause mortality according to a Cox regression model. The optimal cut-off value for the MASCC score was found using Youden's index.</p><p><strong>Results: </strong>The 30-day, 60-day, and 90-day mortality rates were 25.1% (n = 89), 30.2% (n = 107), and 32.7% (n = 116), respectively. Having a hematological malignancy, advanced age, comorbidities, higher levels of C-reactive protein, and procalcitonin on admission, profound neutropenia and a lower MASCC score were statistically different in the mortality group compared to the survival group. The only independent risk factor was the MASCC score to predict all-cause mortality according to the multivariate Cox regression models. A MASCC score below 17 showed a sensitivity of 83.6% and a specificity of 94.1% for predicting all-cause mortality in hospitalized FN patients.</p><p><strong>Conclusions: </strong>In this cohort study, we showed 30, 60 and 90-day mortality rates of hospitalized patients and determined the risk factors. We supported that the MASCC score was an independent risk factor for predicting mortality in hospitalized FN patients. We contributed to the literature by establishing a threshold value for the MASCC score, below 17, showing notably high sensitivity and specificity for predicting all-cause mortality in FN patients.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-9"},"PeriodicalIF":2.5000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546029","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Febrile neutropenia (FN) is linked to significant morbidity and mortality in cancer patients. Therefore, our study aimed to determine the cut-off value of the MASCC score to predict mortality in hospitalized FN patients.

Methods: We included 354 hospitalized cancer patients, divided into two groups: the mortality group (n = 116) and the survival group (n = 238). We defined risk factors of all-cause mortality according to a Cox regression model. The optimal cut-off value for the MASCC score was found using Youden's index.

Results: The 30-day, 60-day, and 90-day mortality rates were 25.1% (n = 89), 30.2% (n = 107), and 32.7% (n = 116), respectively. Having a hematological malignancy, advanced age, comorbidities, higher levels of C-reactive protein, and procalcitonin on admission, profound neutropenia and a lower MASCC score were statistically different in the mortality group compared to the survival group. The only independent risk factor was the MASCC score to predict all-cause mortality according to the multivariate Cox regression models. A MASCC score below 17 showed a sensitivity of 83.6% and a specificity of 94.1% for predicting all-cause mortality in hospitalized FN patients.

Conclusions: In this cohort study, we showed 30, 60 and 90-day mortality rates of hospitalized patients and determined the risk factors. We supported that the MASCC score was an independent risk factor for predicting mortality in hospitalized FN patients. We contributed to the literature by establishing a threshold value for the MASCC score, below 17, showing notably high sensitivity and specificity for predicting all-cause mortality in FN patients.

确定MASCC评分的临界值以预测住院发热性中性粒细胞减少患者的死亡率:一项长达十年的单中心回顾性队列研究
导念:发热性中性粒细胞减少症[FN]与癌症患者的显著发病率和死亡率有关。因此,我们的研究旨在确定MASCC评分的临界值来预测住院FN患者的死亡率。方法:纳入住院肿瘤患者354例,分为死亡组[n=116]和生存组[n=238]。我们根据Cox回归模型定义全因死亡的危险因素。使用约登指数找到MASCC评分的最佳临界值。结果:30天、60天、90天死亡率分别为25.1% [n=89]、30.2% [n=107]、32.7% [n=116]。与生存组相比,死亡组有血液学恶性肿瘤、高龄、合共病、入院时c反应蛋白和降钙素原水平较高、深度中性粒细胞减少症和较低的MASCC评分有统计学差异。根据多变量Cox回归模型,预测全因死亡率的唯一独立危险因素是MASCC评分。MASCC评分低于17时,预测住院FN患者全因死亡率的敏感性为83.6%,特异性为94.1%。结论:在这项队列研究中,我们显示了住院患者30天、60天和90天的死亡率,并确定了危险因素。我们支持MASCC评分是预测住院FN患者死亡率的独立危险因素。我们通过建立一个低于17的MASCC评分的阈值,为预测FN患者的全因死亡率提供了非常高的敏感性和特异性,从而为文献做出了贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology
Oncology 医学-肿瘤学
CiteScore
6.00
自引率
2.90%
发文量
76
审稿时长
6-12 weeks
期刊介绍: Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信